Search
Indinavir
go.drugbank.com/drugs/DB00224ApprovedInvestigationalA potent and specific HIV protease inhibitor that appears to have good oral bioavailability. [PubChem]
Synonyms: (1(1S,2R),5(S))-2,3,5-Trideoxy-N-(2,3-dihydro-2-hydroxy-1H-inden-1-yl)-5-(2-(((1,1-dimethylethyl)amino)carbonyl)-4-(3-pyridinylmethyl)-1-piperazinyl)-2-(phenylmethyl)-D-erythro-pentonamideCategories: P-glycoprotein inducers, P-glycoprotein inhibitorsThonzonium
go.drugbank.com/drugs/DB09552ApprovedIt is also reported that thonzonium also confers an antifungal property and antiresorptive effect on bone. … It is widely used as an additive to in ear and nasal drops to enhance dispersion and penetration of cellular debris and exudate, thereby promoting tissue contact of the administered medication.
Desogestrel
go.drugbank.com/drugs/DB00304ApprovedInvestigational[A176339] It was firstly generated from a study that showed that 11-beta and 11-alkylidene substituent in nortestosterone can enhance the biological activity.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesChymopapain
go.drugbank.com/drugs/DB06752ApprovedWithdrawn[L2482]It is an extracellular plant cysteine proteinase similar to papain in specificity.[A32688] Chymopapain was developed by Chart Medcl and FDA approved on November 10, 1982.
Baxdrostat
go.drugbank.com/drugs/DB19090ApprovedInvestigationaldue to non-selective steroidal activities [A275513, A275514]. … Baxdrostat is an orally bioavailable, highly selective, first-in-class small-molecule aldosterone synthase inhibitor (ASI) designed to block the production of aldosterone [A275512].
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesFremanezumab
go.drugbank.com/drugs/DB14041ApprovedInvestigational[L11779] Along with other recently approved anti-CGRP therapies such as [galcanezumab], [erenumab], and the oral CGRP antagonist [ubrogepant], fremanezumab represents an important step forward in the treatment
Dulaglutide
go.drugbank.com/drugs/DB09045ApprovedInvestigationalDulaglutide, marketed by Eli Lilly as Trulicity, is a once-weekly subcutaneous glucagon-like peptide-1 (GLP-1) receptor agonist designed using recombinant DNA technology; it has been approved as an adjunct
Hexylcaine
go.drugbank.com/drugs/DB00473ApprovedWithdrawnPatients experience an overdose may present with headache, tinnitus, numbness and tingling around the mouth and tongue, convulsions, inability to breathe, and decreased heart function.
Inavolisib
go.drugbank.com/drugs/DB15275ApprovedInvestigationalInavolisib is an inhibitor of PI3Kα that was approved by the FDA in October 2024 for the treatment of certain patients with advanced breast cancers.
Categories: Cytochrome P-450 CYP2B6 Inducers, Cytochrome P-450 Enzyme InducersSynonyms: (2S)-2-((2-((4S)-4-(difluoromethyl)-2-oxo-3-oxazolidinyl)-5,6-dihydroimidazo(1,2-D)(1,4)benzoxazepin-9-yl)amino)propanamide, propanamide, 2-((2-((4S)-4-(difluoromethyl)-2-oxo-3-oxazolidinyl)-5,6-dihydroimidazo(1,2-D)(1,4)benzoxazepin-9-yl)amino)-, (2S)-Letermovir
go.drugbank.com/drugs/DB12070ApprovedInvestigationalLetermovir recieved approval from the FDA on November 8th, 2017 for use in prophylaxis of cytomegalovirus (CMV) infection in allogeneic hematopoietic stem cell transplant patients. It is the first of a new class of CMV anti-infectives ca...
Categories: P-glycoprotein inhibitors, P-glycoprotein substrates